Futuximab/modotuximab - Symphogen

Drug Profile

Futuximab/modotuximab - Symphogen

Alternative Names: 992-and-1024; 992/1024; DS 992/DS 1024; DS-1024/DS-992; Modotuximab/futuximab; Sym-004

Latest Information Update: 31 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Symphogen
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Glioma
  • Phase I Non-small cell lung cancer
  • No development reported Head and neck cancer; Oesophageal cancer

Most Recent Events

  • 23 Oct 2018 Symphogen plans a phase III trial for Colorectal Cancer (Late-stage disease, Second-line therapy or greater) in February 2019 (NCT03717038)
  • 01 Aug 2018 Symphogen initiates a phase II trial for Colorectal cancer in USA (NCT03549338)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top